United Drug (UDG)
market vs.
industry GROWTH & VALUE
| 12m Forecast Rolling | ||||
| PE Ratio (f) | 13.3 |
|
|
|
| PEG Ratio (f) |
|
|
||
| EPS Growth (f) | % |
|
|
|
| Dividend Yield (f) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | 2.18 |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry QUALITY
| Year End 30th Sep | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013E | 2014E | CAGR / Avg | |
| Revenue | €m | |||||||||
| Operating Profit | €m | |||||||||
| Net Profit | €m | |||||||||
| EPS Reported | € | |||||||||
| EPS Normalised | € | |||||||||
| EPS Growth | % | |||||||||
| PE Ratio | x | |||||||||
| PEG | x | |||||||||
| Profitability | ||||||||||
| Operating Margin | % | |||||||||
| ROA | % | |||||||||
| ROCE | % | |||||||||
| ROE | % | |||||||||
| Cashflow | ||||||||||
| Op. Cashflow ps | € | |||||||||
| Capex ps | € | |||||||||
| Free Cashflow ps | € | |||||||||
| Last ex-div: 16th May, paid: 13th Jul more... Dividends | ||||||||||
| Dividend ps | € | |||||||||
| Dividend Growth | % | |||||||||
| Dividend Yield | % | |||||||||
| Dividend Cover | x | |||||||||
| Balance Sheet | ||||||||||
| Cash etc | €m | |||||||||
| Working Capital | €m | |||||||||
| Net Fixed Assets | €m | |||||||||
| Net Debt | €m | |||||||||
| Book Value | €m | |||||||||
| Average Shares | m | |||||||||
| Book Value ps | € | +4.3% | ||||||||
FINANCIAL BRIEF: For the fiscal year ended 30 September 2012, United Drug PLC revenues increased 5% to EUR1.83B. Net income increased 31% to EUR47.7M. Revenues reflect Health Care Supply Chain segment increase of 3% to EUR1.46B, Packaging and Speciality segment increase of 16% to EUR160.6M, Contract Sales Outsourcing segment increase of 7% to EUR213.9M, United States segment increase of 28% to EUR159M. more »
| Leverage (ttm) | Total | Ex Intang | |||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % | ||||
| Liquidity (ttm) | ||
| Current Ratio | ||
| Quick Ratio | ||
| Interest Cover | ||
| Efficiency (ttm) | ||
| Asset Turnover | ||
| Rec's Turnover | ||
| Stock Turnover | ||
market vs.
industry RECENT HISTORY
| Latest interim period (ended 30th Sep '12) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Average Annualised | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
BROKER CONSENSUS & FORECAST TREND
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: | 1 | 0 | 1 | 2 | 1 |
United Drug plc is a provider provides outsourced commercial solutions to international healthcare companies. The Company specialize in supply chain, packaging, sales and marketing, medical and regulatory services. The Company operates through three divisions: Healthcare Supply Chain, Packaging & Specialty, Sales, Marketing & Medical. Sales, Marketing & Medical provides contract sales outsourcing and related marketing and regulatory services to healthcare manufacturers. Healthcare Supply Chain combines all of the Company’s healthcare logistics based businesses. Packaging & Specialty provides outsourced packaging solutions for pharmaceutical manufacturers. On August 20, 2012, the Company confirmed the completion of the acquisition of the United Kingdom and the United States clinical services businesses combined (Bilcare Global Clinical Supplies or Bilcare GCS) from Bilcare Limited.
Directors: Liam FitzGerald (CEO) 48, Chris Corbin (Mgng.Dir.) 56, Alan Ralph (Exec. Dir.) 43, Mike Gannon (Secy.) , Barry McGrane (Non Ex. Dir.) 49,
No. of Employees: 4,612 No. of Shareholders: n/a
| Last Annual | September 30th, 2012 |
| Last Interim | September 30th, 2012 |
| Shares in Issue | 239,755,633 |
| Free Float | 191.0m (79.7%) |
| Sector | Healthcare |
| Industry | Healthcare Equipment & Supplies |
| Index | FTSE 350 Act , FTSE Lower Yield , FTSE 250 Mid , FT350 Fd&drg Ret , |
| Exchange |
London Stock Exchange (Full) |
| Eligible for | an ISA? a SIPP? |
| Address | United Drug House,Magna Drive Citywest Road, Magna Business Park Dublin 24, DUBLIN, 24, Ireland |
| Web | http://www.united-drug.com |
| Phone | +353 1 4632300 |
| Contact | () |
| Auditors | KPMG |
| Tue 5:14pm | Director/PDMR Shareholding |
| 9th May | Half Yearly Report |
| 8th May | Director Declaration |
| 2nd Apr | Total Voting Rights |
| 25th Mar | Holding(s) in Company |
| 25th Mar | Holding(s) in Company |
Recent ↓
